An observational study in Estradiol Receptor Polymorphism, Progesterone Receptor Polymorphism and IVF, sponsored by Infertility Treatment Center Dortmund. Completed at 1 site in Germany. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-03-25.
Sponsored by Infertility Treatment Center Dortmund · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Infertility with a site in Germany — 4 open to participants now, 4 under way, none of them phase 3. Infertility · Germany.
Among the 28 studies in Infertility with a site in Germany, this one is the 9th largest by enrollment of the 10 observational ones that give a count, is one of 4 that started in 2010, is one of 10 observational ones, and was the 10th registered.
2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →4 of the 28 studies in Infertility with a site in Germany are open now. Recruiting first, the newest first:
Prof. Dr. med. M.Sc. Georg Griesinger · Sites in Germany
Ages 18–44 · Women only
Infertility Treatment Center Dortmund · Sites in Germany
Ages 18+ · Women only · Healthy volunteers
University of Luebeck · Sites in Germany
Ages 18–44
University of Luebeck · Sites in Germany
Ages 18–45 · Women only
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 18 Years to 40 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 4 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 150 is below the median of 200 across 592 observational studies indexed under Infertility.
Median enrollment 137 across the 18 interventional studies, 1,023 across the 10 observational. Of the 23 that completed or were terminated, 7 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 28 have an industry lead sponsor. The 10 most frequent:
Infertility Treatment Center Dortmund is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Infertility Treatment Center Dortmund has 2 studies filed under Infertility — fewer than ten, so there is no comparison to draw.
2 of the studies in Infertility with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06995261Prof. Dr. med. M.Sc. Georg GriesingerFollitropin Delta in Long GnRH-agonist Protocol | 2027-04 |
| NCT03507673University of LuebeckClinical Cohort Study on the Endocrinology and Vaginal/Endometrial Microbiome of the Luteal Phase in Assisted Reproduction | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 28 studies in Infertility with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Estradiol is synthesized by granulosa cells of ovaries under control of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). It is known that Estradiol plays a crucial role in maturation and fertilization of oocytes. Furthermore it is involved in development of secondary female sexual organs, fertility and maintenance of pregnancy.
Estradiol influences these processes by binding to estradiol receptors (ER). They are ligand-depending transcription-factors. In humans there are two subtypes: ERa and ERb, which are synthetized from gene ESR1 on chromosome 6 and ESR2 on chromosome 14. Both subtypes are expressed in the ovary. Both genes are polymorph. Especially for ERa subtype several polymorphisms and mutations are known which can be linked to breast cancer, spontaneous abortions, osteoporosis and the point in time of menarche. Furthermore some studies have shown a relationship between certain polymorphisms and the risk of infertility associated gynecological malfunctions and the result of IVF treatments.
Progesterone is a hormone which plays a crucial role in initiation and maintenance of pregnancy. It induces the transformation of the endometrium, which facilitates the implantation of the fertilized oocyte and supports the pregnancy. Progesterone acts by binding to its receptor. The gene for this receptor is polymorph within the population, whereas some variants seem to account for implantation failure of embryos.
In the investigators study the investigators will analyse the role of ERP and PRP polymorphisms in the context of IVF treatment. The analyzed genotypes are two polymorphisms of ESRI, called Pvu and Xba, as well as a variant of ESRII, ER2. In the progesterone receptor gene a single nucleotide exchange at position +331 (G->A) plays a role.
The parameters correlated with are concentrations of estradiol, progesterone and FSH, number of follicles, number of fertilized oocytes and pregnancy rate.
The investigators hope to optimize established treatment protocols and to improve the chances of success of IVF treatments depending on the genotype of the patient.
Female patients at reproductive age seeking IVF treatment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
females with \>15 follicles or E2\>3000 after treatment with gonadotropins
patients with \<3 follicles or no response to treatment with gonadotropins
females with an indication for treatment because of male subfertility
genetic testing for two estrogene receptor genes, correlating to numbers of oocytes retrieved at oocyte punction after hormonal stimulation
Time frame: 30.06.2013
The record gives a start of Oct 2010, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Infertility Treatment Center Dortmund